Getting 3.75 mg Mounjaro from a 2.5 mg Pen: What the Numbers Actually Mean

Why 3.75 mg cannot come from a 2.5 mg pen

The Mounjaro KwikPen is an auto-injector with a pre-filled, pre-set cartridge. When you press the button, the mechanism delivers exactly the dose printed on the label, no more, no less. There is no dial, no plunger to partially depress, and no reservoir you can draw from with a separate syringe. A 2.5 mg pen contains the right amount of tirzepatide solution to deliver 2.5 mg over four weekly injections (one injection per week from the same pen). There is no physical mechanism by which 3.75 mg could be obtained from it.

If 3.75 mg appears in a search, it most commonly arises from one of two places: curiosity about what 3.75 mg Mounjaro represents as a concept, or confusion about how doses from the 5 mg pen can be split. The 5 mg pen, used differently, is where that figure occasionally crops up in clinical discussions, and you can read more about how 3.75 mg from the 5 mg pen works in a separate guide covering that pen entirely.

The practical upshot is straightforward. If you are currently on 2.5 mg and wondering whether there is an intermediate step before 5 mg, the licensed titration schedule does not include one. Your prescriber will assess whether you are ready to move to the 5 mg strength, and that decision turns on how you have tolerated the starter dose, not on whether a fraction of it can be extracted and combined.

What the 2.5 mg starting dose is actually for

The starter dose exists to settle your system, not to drive weight loss. At 2.5 mg, tirzepatide begins slowing gastric emptying and interacting with GIP and GLP-1 receptors, but the primary purpose of the first four weeks is tolerability. Nausea, constipation, and other gastrointestinal effects tend to be most noticeable when treatment begins or after a dose increase; starting low gives the body time to adapt before the dose climbs.

This is why the BNF entry for tirzepatide describes 2.5 mg as an initiation dose, with increases typically every four weeks based on clinical review. The therapeutic weight-management effect builds over subsequent doses and months of treatment. Trying to engineer a dose halfway between the first and second step would not accelerate results, it would simply bypass the safety logic built into the titration schedule.

People sometimes ask whether slowing down titration by staying at 2.5 mg longer is an option if side effects are significant. That is a legitimate clinical question, and a prescriber can advise on it. What is not a legitimate option is improvising an unlicensed intermediate dose by manipulating a pen that was never designed to allow it. A question our prescribers hear regularly is whether the titration can be personalised, it can, but through clinical oversight, not self-adjustment.

Deciding whether you are ready to move beyond 2.5 mg

The decision to escalate your dose is exactly that: a decision, made with a prescriber who has reviewed how you have responded to the starter pen. Factors that typically matter include how well you have tolerated the GI effects, whether you have been able to maintain the once-weekly injection schedule, and your weight trajectory. No single factor is automatically decisive.

At nume, every dose change goes through the same clinical review process as the first prescription. A real clinician reads your update (not an automated system) before any new pen is dispatched. If you have been wondering about cost as your treatment progresses, the Mounjaro pricing page explains how treatment costs change across dose steps. Your pen arrives via DPD the next working day in plain, unbranded packaging, so there is no guessing about what is in the box or when it lands.

If you are currently prescribed 2.5 mg and feel ready to discuss your next step, or if you have been transferring from another provider and want clarity on where you are in the titration sequence, a prescriber review is the right starting point. You can also read more about Mounjaro as a treatment or explore the broader weight-loss treatment options available through a regulated UK pharmacy.

A note on online claims about splitting or modifying pens

Occasionally, forums or social media posts describe attempts to extract a portion of a Mounjaro pen's dose or combine partial injections from different pens to reach an intermediate amount. None of this has a basis in the licensed prescribing information, and the risks are real: incorrect dosing, contamination from improper handling, and use of a medicine in a way that has not been clinically assessed for safety. The MHRA has warned publicly about unsafe practices around GLP-1 medicines, and manipulating a pen that was not designed for partial extraction falls squarely into that category. It is also worth noting that some products marketed online as Zepimax tirzepatide are not licensed in the same way as approved pens, which adds a further layer of risk for anyone considering alternatives outside regulated channels.

If you have questions about your specific situation (including what to do if a dose does not feel right) the right person to ask is your prescriber, not a forum thread. Anyone dispensing these medicines without a prescription is operating outside the law, regardless of what intermediate dose they claim to offer. The nume FAQs cover common questions about how the consultation and dose-review process works, and the clinical team behind nume's prescribing is named and verifiable.